LONDON, Dec. 8, 2020 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the introduction of RI.INSIGHTS, the first platform designed to enable orthopaedic surgeons to benchmark robotics surgical experiences with other users to optimize surgical planning and improve patient reported outcome measures (PROMs).
Previously, surgeons were unable to review complex robotics surgical information for individual patients or benchmark against their peers. RI.INSIGHTS collects intra and post-op data during robotics-assisted procedures and then presents this data alongside post-op patient outcomes allowing surgeons to gain insights of their robotics-assisted surgical procedures.
The RI.INSIGHTS platform is a key addition to Smith+Nephew’s Real Intelligence portfolio of products and solutions – including the CORI™ Surgical System – introduced earlier this year.
“The launch of RI.INSIGHTS further strengthens Smith+Nephew’s Real Intelligence platform and underscores our advancement into digital health,” said Skip Kiil, President of Global Orthopaedics for Smith+Nephew. “We are excited for surgeons to start using the insights provided by strong clinical data collected by the platform to drive improved patient outcomes.”
“The RI.INSIGHTS platform maps the future of robotics and digital surgery,” said Dr. Nathwani, Consultant Orthopedic Surgeon, Imperial College Healthcare, NHS Trust and The London Clinic. “Robotics has proven accuracy, and using the wealth of individualized intra and post-op planning data that RI.INSIGHTS delivers, we can analyse surgical parameters like never before to provide the best customized robotic solutions for our patients.”
“Today, with RI.INSIGHTS we can streamline robotics surgery with proven accuracy, where the data I collect as a surgeon can drive my surgical decisions before making a bone cut. Additionally, the outcomes data collected after the surgery provides a feedback loop that can validate those surgical decisions, allowing us to further refine our surgical goals,” said Dr. Jimmy Chow, Orthopaedic Surgeon for Hip and Knee, Orthopedic Institute of the West. “Tomorrow, we hope to be able to change the shape of orthopedics through data. The RI.INSIGHTS platform is sophisticated enough to one day identify, qualify, and even guide future surgeons’ decisions. We hope to elevate the level of all surgeries and outcomes for all patients.”
RI.INSIGHTS is available on a limited basis, with a full commercial release following in 2021. To learn more about Smith+Nephew’s Real Intelligence ecosystem, please visit www.smith-nephew.com/professional/products/robotics/real-intelligence/.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc